What New Kratom Research Means for Consumer Safety and Product Liability

Kratom continues to generate debate among researchers, regulators, healthcare providers, and consumers across the U.S. A recent announcement from the National Institutes of Health (NIH) has renewed interest in the substance after federal regulators authorized a Phase I clinical trial involving mitragynine, the primary psychoactive compound found in kratom. Researchers hope the study will help determine whether a purified form of mitragynine could eventually play a role in treating opioid use disorder.

The announcement also serves as a reminder that scientific research into kratom is still evolving and that important questions remain about many kratom products being sold in the marketplace.

The Kratom Compound Being Studied Is Different From Many Retail Products

Consumers often hear the word “kratom” used broadly, but researchers and regulators are frequently talking about very different products.

The NIH-approved study involves purified mitragynine produced under strict scientific standards. Researchers will evaluate the compound through a carefully monitored clinical trial designed to assess safety and tolerability in human subjects.

Commercial kratom products, by contrast, have historically been sold in a wide variety of forms, including powders, capsules, extracts, beverages, gummies, and concentrated products. The strength, purity, ingredients, and manufacturing processes used to create these products can vary significantly from one to another.

This distinction is important because consumers often assume that all kratom products are essentially the same. In reality, products sold under the kratom label may contain different concentrations of active compounds and may be manufactured under very different quality-control standards.

Why Kratom Safety Concerns Continue Despite New Research

The new federal research doesn’t eliminate longstanding concerns about kratom safety. Federal agencies have repeatedly warned consumers that the FDA has not approved kratom for the treatment of any medical condition. Regulators have also raised concerns about contamination, inaccurate labeling, adverse health effects, and potential dependence among some users.

Over the past several years, reports involving poison control centers, emergency medical treatment, hospitalizations, and deaths allegedly linked to kratom exposure have continued to attract attention from public health officials and lawmakers.

These kratom dangers have contributed to shaping policy decisions about kratom sales in multiple states.

Louisiana’s Kratom Ban Reflects Ongoing Safety Questions

Louisiana lawmakers ultimately chose to prohibit kratom sales within the state amid growing concerns about consumer safety. The state’s decision was influenced by reports of adverse health events, questions about product consistency, and concerns about the lack of regulatory oversight surrounding many kratom products.

Although federal researchers are now studying a purified kratom compound, the NIH trial doesn’t change Louisiana law. Nor does it establish that commercially available kratom products are safe or effective.

Louisiana lawmakers concluded that the existing safety concerns surrounding kratom justified action before more definitive answers became available from the scientific community.

Why Kratom Lawsuits Are Being Filed

The growing number of kratom-related injuries has also led to litigation against certain manufacturers and sellers. Kratom lawsuits generally don’t focus on the plant itself. Instead, they often center on questions about product safety, consumer warnings, product formulation, contamination, marketing practices, and whether companies adequately disclosed potential risks.

Some of the most serious kratom lawsuits involve wrongful death claims brought by families who allege that a kratom product contributed to the loss of a loved one. These cases often raise questions about what manufacturers knew about potential risks, what warnings were provided to consumers, and whether safer practices could have prevented tragedy.

Like many dangerous product cases, kratom litigation often centers on whether consumers were given accurate information about potential risks and if manufacturers took reasonable steps to make their products safe.

While every case is different, these lawsuits are helping uncover information about how certain kratom products were developed, marketed, and sold to consumers.

How HKGC Helps People Harmed by Dangerous Kratom Products

At Herman, Katz, Gisleson & Cain, our attorneys have decades of experience representing individuals and families harmed by dangerous and defective products. Product liability cases often involve complex questions regarding product design, manufacturing practices, warnings, regulatory compliance, and corporate decision-making. 

HKGC has been at the forefront of kratom litigation in Louisiana. Our firm filed what is believed to be the first Louisiana wrongful death kratom lawsuit and is representing families seeking answers after devastating losses linked to kratom products. Through these cases, our attorneys are investigating issues involving product warnings, marketing practices, and the safety of products sold to consumers.

Whether a case involves kratom, pharmaceutical products, consumer goods, industrial equipment, or other dangerous products, our goal is to help injured individuals understand their rights and pursue accountability when appropriate.

As scientific research continues and courts evaluate claims involving kratom injuries, consumers deserve clear information about their legal rights. Individuals harmed by dangerous products shouldn’t have to navigate these issues alone.

If you or a loved one suffered serious injuries after using kratom, or if you have questions about a potentially dangerous product claim, the attorneys at Herman, Katz, Gisleson & Cain are available to discuss your situation. Contact our team online, via live chat, or by calling 844-943-7626 for a free and confidential consultation.